High Content Positional Biosensor Assay to Screen for Compounds that Prevent or Disrupt Androgen Receptor and

Yun Hua1, Daniel P Camarco1, Christopher J Strock2

  • 1Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Room 586 Salk Hall, 3501 Terrace Street, Pittsburgh, PA, 15261, USA.

Insights

A new biosensor assay screens for drugs targeting the Androgen Receptor (AR) and Transcriptional Intermediary Factor 2 (TIF2) interaction, crucial in prostate cancer progression. This method identifies compounds that modulate AR-TIF2 interactions to combat castration-resistant prostate cancer (CRPC).

Area of Science:

  • Molecular Biology
  • Biochemistry
  • Oncology

Background:

  • Transcriptional Intermediary Factor 2 (TIF2) is a key coactivator for the Androgen Receptor (AR).
  • AR-TIF2 interactions are implicated in the development and progression of castration-resistant prostate cancer (CRPC).
  • Targeting AR-TIF2 interactions offers a potential therapeutic strategy for CRPC.

Purpose of the Study:

  • To develop and implement a biosensor assay for screening small molecules targeting AR-TIF2 protein-protein interactions (PPIs).
  • To identify compounds that can induce, inhibit, or disrupt AR-TIF2 PPIs.
  • To provide a cell-based, scalable screening method for potential CRPC therapeutics.

Main Methods:

  • Development of an AR-TIF2 protein-protein interaction (PPI) biosensor using fluorescent protein reporters (AR-RFP and TIF2-GFP).
  • Utilized high-content imaging and analysis to quantify AR-TIF2 PPIs.
  • Employed recombinant adenovirus (rAV) for homogeneous and scalable expression of biosensor components.

Main Results:

  • The biosensor assay successfully recapitulates ligand-induced AR translocation and AR-TIF2 complex formation.
  • AR-RFP co-localizes with TIF2-GFP in nucleoli upon Dihydrotestosterone (DHT) exposure, indicating successful AR-TIF2 interaction.
  • The assay is scalable and suitable for high-throughput screening.

Conclusions:

  • The AR-TIF2 PPI biosensor is a promising tool for identifying modulators of AR transcriptional activity.
  • This approach may lead to novel therapeutics that overcome resistance mechanisms in CRPC.
  • Cell-specific modulation of AR activity offers a targeted strategy against prostate cancer progression.

Related Concept Videos